[go: up one dir, main page]

AR033650A1 - TREATMENT OF COMBINATION WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1 - Google Patents

TREATMENT OF COMBINATION WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1

Info

Publication number
AR033650A1
AR033650A1 ARP000104779A ARP000104779A AR033650A1 AR 033650 A1 AR033650 A1 AR 033650A1 AR P000104779 A ARP000104779 A AR P000104779A AR P000104779 A ARP000104779 A AR P000104779A AR 033650 A1 AR033650 A1 AR 033650A1
Authority
AR
Argentina
Prior art keywords
release
combination
processing
inhibit
compounds
Prior art date
Application number
ARP000104779A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR033650A1 publication Critical patent/AR033650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos y composiciones para tratar y prevenir estados morbosos mediados por la interleuquina 1(I1-1). En los métodos y las composiciones se usa un polipéptido antagonista del receptor de la interleuquina 1(I1-1ra), o una variante del mismo, en combinación con un agente no esteroide que inhibe el procesamiento y la liberación de I1-1.Methods and compositions for treating and preventing morbid conditions mediated by interleukin 1 (I1-1). In the methods and compositions an interleukin 1 receptor antagonist polypeptide (I1-1ra), or a variant thereof, is used in combination with a non-steroid agent that inhibits the processing and release of I1-1.

ARP000104779A 1999-09-14 2000-09-12 TREATMENT OF COMBINATION WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1 AR033650A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
AR033650A1 true AR033650A1 (en) 2004-01-07

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104779A AR033650A1 (en) 1999-09-14 2000-09-12 TREATMENT OF COMBINATION WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (en)
JP (1) JP2003509378A (en)
AR (1) AR033650A1 (en)
AU (1) AU6464400A (en)
BR (1) BR0014003A (en)
CA (1) CA2383026A1 (en)
CO (1) CO5190701A1 (en)
EC (1) ECSP003652A (en)
GT (1) GT200000155A (en)
PA (1) PA8502901A1 (en)
PE (1) PE20010685A1 (en)
TN (1) TNSN00183A1 (en)
WO (1) WO2001019390A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557910C (en) 2004-04-02 2012-05-29 Amgen Inc. Methods of reducing aggregation of il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
IL253661B2 (en) * 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a pentagonal ring, pharmaceutical preparations and their uses
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
JP7050751B2 (en) * 2016-04-18 2022-04-08 ノバルティス アーゲー Compounds and compositions for treating conditions associated with NLRP activity
MA55695A (en) 2017-01-23 2022-02-23 Genentech Inc CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
CA3059458A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
DK3661925T3 (en) 2017-07-07 2022-02-28 Inflazome Ltd STILL UNKNOWN SULPHONAMIDE CARBOXAMIDE COMPOUNDS
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
HRP20240521T1 (en) 2017-07-24 2024-07-05 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
MA49903A (en) * 2017-08-15 2020-06-24 Inflazome Ltd SULPHONYLURIDES AND SULPHONYLTHIOURIDES AS NLRP3 INHIBITORS
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TW201910317A (en) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 Novel compound
KR20200041337A (en) 2017-08-15 2020-04-21 인플라좀 리미티드 Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited Novel substituted sulfonylurea derivatives
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
MA50567A (en) 2017-11-09 2020-09-16 Inflazome Ltd NEW SULFONAMIDE CARBOXAMIDE COMPOUNDS
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759073A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
EP3817817A1 (en) 2018-07-03 2021-05-12 Novartis AG Nlrp modulators
UA128558C2 (en) 2018-07-20 2024-08-14 Ф. Хоффманн-Ля Рош Аг Sulfonimidamide compounds as inhibitors of interleukin-1 activity
EP3823726A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche SA Sulfonylurea compounds as inhibitors of interleukin-1 activity
BR112021002770A2 (en) 2018-08-15 2021-05-04 Inflazome Limited innovative sulfonamideurea compounds
EP3870565A1 (en) * 2018-10-24 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
MY209594A (en) 2019-01-14 2025-07-23 Zydus Lifesciences Ltd Novel substituted sulfonylurea derivatives
EP4157860A4 (en) * 2020-05-25 2024-03-06 Beijing Vdjbio Co., Ltd. INTERLEUKIN-1 RECEPTOR ANTAGONIST AND FUSION PROTEIN CONTAINING IT

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP0964849B1 (en) * 1997-01-29 2003-06-04 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
AU6464400A (en) 2001-04-17
EP1214087A1 (en) 2002-06-19
GT200000155A (en) 2002-03-08
BR0014003A (en) 2002-05-21
WO2001019390A1 (en) 2001-03-22
JP2003509378A (en) 2003-03-11
CO5190701A1 (en) 2002-08-29
CA2383026A1 (en) 2001-03-22
ECSP003652A (en) 2002-04-23
PE20010685A1 (en) 2001-07-03
PA8502901A1 (en) 2002-02-21
TNSN00183A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
AR033650A1 (en) TREATMENT OF COMBINATION WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1
MX9203444A (en) MEDICINES.
UY26296A1 (en) DRUG TREATMENT OF INQUIET LEGS SYNDROME
ES2146300T3 (en) USE OF ANTIHELMINTIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS CAUSED BY ANOPLOCEPHALA PERFOLIATA IN EQUIDS.
ES2188177T3 (en) COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, WHICH INCLUDES PROPIONIL-L-CARNITINE AND GENISTEINE.
ECSP045407A (en) BENZAZOLES SUBSTITUTED AND THE USE OF THE SAME AS INHIBITORS OF QUINASA RAF
UY26391A1 (en) SGLT2 INHIBITORS OF C-ARYL GLUCOSIDES AND METHOD
UY27465A1 (en) METHODS AND COMPOSITIONS TO TREAT FLAVIVIRUS AND PESTIVIRUS WITH 4 'NUCLEOSID MODIFICATIONS
MX9304775A (en) BENZOXAZINONES AS REVERSE HIV TRANSCRIPTASE INHIBITORS.
CO5160262A1 (en) PHARMACEUTICAL FORMULATIONS OF CONTROLLED LIBERATION
ATE333896T1 (en) VASCULARIZATION INHIBITORS
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
PE20010642A1 (en) PRAMIPEXOL AND CLONIDINE COMBINATION FOR THE TREATMENT OF RESTLESS LEGS SYNDROME
BR0112212A (en) A combination of fbpase inhibitors and antidiabetic agents useful for treating diabetes.
MX9304595A (en) DERIVATIVES OF 1,2,4-TRIAZOLA SUBSTITUTED IN 4
AR043660A1 (en) THE TREATMENT OF ALZHEIMER'S DISEASE
AR028730A1 (en) PROCEDURE FOR FINDING COMPOUNDS THAT ARE SUITABLE FOR THE TREATMENT AND / OR PROFILAXIS OF OBESITY AND USE OF SUCH COMPOUNDS
UY28007A1 (en) THERAPEUTIC TREATMENT
AR021690A1 (en) USE OF KTQ1 CHANNEL INHIBITORS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES, WHICH ARE CAUSED BY YECTOPARASITES HELMENTS.
AR046402A1 (en) COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROBENCENOSULPHONIC COMPOUND AND A POTASSIUM CHANNEL MODULATOR
AR034975A1 (en) METHOD FOR THE TREATMENT OF PRIMARY INSOMNIA
CO5251423A1 (en) TREATMENT OF ENDOMETRIOSIS OR INFERTILITY, OR IMPROVEMENT OF FERTILITY
UY25103A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS
UY26336A1 (en) COMBINATION TREATMENT WITH I1-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF I1-1.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal